Published in Healthcare Finance, Tax and Law Weekly, December 6th, 2006
The net loss available to common shareholders for the 3 months ended September 30, 2006 was $6.9 million or $0.24 per share compared to $2.3 million or $0.15 per share for the 3 months ended September 30, 2005. The increase in the net loss reflects increased development expenses related to cethromycin pivotal phase III clinical trial costs.
"We are focused on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.